(Q35048758)

6 August 2017

1 reference

title

Considerations in the design and development of transport inhibitors as adjuncts to drug therapy (English)

1 reference

6 August 2017

Anne H Dantzig

1

1 reference

6 August 2017

Dinesh P de Alwis

series ordinal

2

1 reference

6 August 2017

Michael Burgess

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Advanced Drug Delivery Reviews

6 August 2017

1 reference

6 August 2017

55

1 reference

6 August 2017

133-150

1 reference

6 August 2017

1

1 reference

ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Overview: ABC transporters and human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Transport of leukotriene C4 and structurally related conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

MRP3, an organic anion transporter able to transport anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

MRP subfamily transporters and resistance to anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The role of half-transporters in multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Role of transport proteins in drug absorption, distribution and excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The functional role of P-glycoprotein in the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Inhibitors of multidrug resistance to antitumor agents (MDR).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Clinical trials of agents that reverse multidrug resistance. A literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Multiple cytochrome P-450 subfamilies are co-induced with P-glycoprotein by both phenothiazine and 2-acetylaminofluorene in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Induction of cytochromes P450.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Clinical pharmacokinetics of vinorelbine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

A family of drug transporters: the multidrug resistance-associated proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Bilary disposition of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Increased drug delivery to the brain by P-glycoprotein inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Visualization of multidrug resistance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

Future perspectives for the development of P-glycoprotein modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900175-8

7 January 2021

10.1016/S0169-409X(02)00175-8

Identifiers

DOI

1 reference

6 August 2017

1 reference